Selection of a suitable graft for allogeneic hematopoietic stem cell transplantation involves consideration of both donor and recipient characteristics. Of primary importance is sufficient donor-recipient human leukocyte antigen (HLA) matching to ensure engraftment and acceptable rates of graft-versus-host disease. In this perspective, the National Marrow Donor Program (NMDP) and the Center for International Blood and Marrow Transplant Research (CIBMTR) provide guidelines, based on large studies correlating graft characteristics with clinical transplantation outcomes, on appropriate typing strategies and matching criteria for unrelated adult donor and cord blood graft selection.
the NMDP and CIBMTR. Associations between HLA disparity and survival differ somewhat among published studies. [3] [4] [5] [6] [7] These differences are detailed in previous publications 1, 2 and likely result from differences in study design, e.g., sample size, recipient race/ethnicity, categorization of mismatches, impact of other recipient variables such as diagnosis and disease stage.
However, taken together, these studies support two general concepts. First, there is a direct association between the number of donor-recipient HLA mismatches and the risk for mortality.
Second, mismatching has a greater impact on absolute mortality differences in recipients with "low-risk" disease, i.e., disease with a low risk of post-transplantation recurrence. One limitation of existing large studies is that they primarily evaluate the impact of HLA-matching on outcome of transplantation for malignant disease. Fewer data are available for transplantation of nonmalignant disorders, but the general principles are presumed to apply. One caveat to this is that graft-versus-tumor effects that offset some of the mortality associated with graft-versus-host disease after transplantation for malignancies are of no benefit when treating non-malignant diseases.
Which is the most important outcome to consider?
The outcome of primary importance after transplantation is survival. Survival is determined by multiple factors. Pre-transplantation factors include donor-recipient HLA matching, graft cell-dose (particularly for umbilical cord blood grafts), recipient cytomegalovirus seropositivity, performance score, disease, and disease status. Post-transplantation factors include acute and chronic graft-versus-host disease (GVHD), infections, organ toxicity, and recurrent and second malignant neoplasms. When transplantation is being considered as a treatment option, early referral for transplantation, ensuring the recipient
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What are the optimal match criteria for unrelated adult donors? Our proposed guidelines are based on several studies that analyzed the effect of donor-recipient HLA match on survival. 3, 4, 8, 9 The study by Lee et al 9 of 3,857 transplantations for hematologic malignancies, using primarily marrow grafts, showed that high-resolution matching for HLA-A, -B, -C, and -DRB1 maximizes post-transplantation survival. This NMDP/CIBMTR study isolated the effect of each locus by comparing mismatches at a particular locus within recipients who were highresolution matched for all other loci. Matching at all four loci was important and there was a direct association between the number of HLA mismatches and the risk for mortality. This study also found that a high-resolution mismatch had an effect similar to an antigen-level mismatch.
The possible exception was HLA-C where high-resolution mismatches appeared to be better tolerated than antigen-level mismatches. Recipient-related factors were also important, particularly disease stage at transplantation. The magnitude of the survival differences with HLA mismatching was greatest (about 10% lower with each mismatch) among recipients with "low-risk" disease (defined as chronic myelogenous leukemia in first chronic phase, myelodysplastic syndrome subtype refractory anemia, acute leukemia in first remission).
Among recipients with "high-risk" disease, the higher mortality associated with HLA mismatching was statistically significant but of lesser magnitude (≤5% lower with each mismatch).
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If a mismatch is unavoidable, a single locus mismatched donor (HLA-A, -B, -C, or -DRB1) can be used with acceptable risks of transplant-related mortality. The study suggested that mismatches at HLA-B and -C may be less detrimental than those at HLA-A and -DRB1, but the data supporting this difference was not conclusive.
Of importance is the observation in the Lee et al study that an isolated mismatch at HLA-DQ did not have the same impact as mismatching at the four other HLA loci, 9 although other data indicate that HLA-DQ mismatches may be important in certain disease subsets or when coupled with mismatches at other loci. 6 ,10 Similar to HLA-DQ, mismatches at HLA-DP did not seem to affect overall mortality in the Lee study. Several studies, including the Lee study, 5, 9, 11 show an association between HLA-DP mismatches and acute GVHD; however, this negative impact is offset by a decreased risk for disease relapse with no net effect on survival. 11 Additional work by Zino et al, 12 subsequently confirmed in a large International Histocompatibility Working Group study, 13 suggests that the nature of the DP mismatch may determine its effect. These studies characterized DP mismatches as permissive or non-permissive based on whether they occurred within or between cross-reactive T-cell epitope groups. Non-permissive mismatching was associated with higher risks of non-relapse mortality, especially when there was additional mismatching at other loci. 12, 14 In further analysis of the dataset used by Lee et al, mismatching at HLA-DRB3, -DRB4, and -DRB5 did not appear to impact outcome when appearing in isolation, but multiple mismatches at secondary HLA loci, i.e., HLA-DQ, -DP, and -DRB3/4/5, increased the risk associated with mismatching at HLA-A, -B, -C, or -DRB.
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For personal use only. on October 28, 2017 . by guest www.bloodjournal.org From Do HLA matching requirements differ in selection of adult peripheral blood stem cell donors? Currently, most unrelated adult donor transplantations use granulocyte colonystimulating factor mobilized peripheral blood stem cell (PBSC) grafts. The analyses of highresolution HLA-matching discussed above mainly derive from studies of transplantations using myeloablative conditioning regimens and marrow grafts. PBSC and marrow grafts differ in both the number and relative proportion of cells, including CD3+ and CD34+ cells, which might influence the effects of HLA matching. In a separate NMDP/CIBMTR analysis of HLA matching in 1933 unrelated PBSC transplantations for hematologic malignancies, 16 recipients of PBSC grafts with at least one HLA antigen level mismatch at HLA-A, -B, -C, or -DRB1 had worse disease-free and overall survival than those receiving an 8/8 matched graft. No significant effect was observed when the mismatch was at the allele-level only, but there were far fewer patients evaluable for these comparisons than in the Lee et al study 9 and the power to detect a difference was limited. As seen with marrow grafts, survival was not affected by mismatching at either HLA-DQ or -DP. Notably, HLA-C antigen mismatching conferred the greatest risk for mortality, grade III-IV acute GVHD and chronic GVHD. The adverse effect of mismatching at the HLA-C locus was significant for recipients treated with either myeloablative or reduced intensity conditioning regimens.
In situations where HLA-C mismatching cannot be avoided, one might wonder whether a marrow graft would be better tolerated than PBSC. In an exploratory analysis that compared the PBSC data set to the marrow data set used for the Lee analysis, 16 no advantage was found to 
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The NMDP donor file includes volunteers from the U.S. as well as Germany, Israel, The Netherlands, Norway, and Sweden. The NMDP cord blood inventory contains units from U.S. banks as well as Germany, Israel, Singapore, and Taiwan. An NMDP search includes a general search of Bone Marrow Donors Worldwide (BMDW), 28 as well as an automatic detailed search of certain international registries using the EMDIS (European Marrow Donor Information System) network. The BMDW report is particularly helpful to set an optimal, but realistic, target for an international donor search. Searches can also be submitted directly to BMDW to view potentially matched donors/units in differing formats. However, the decision on the overall search strategy and the usefulness of an extended international search must also take into account the variation of allele and haplotype frequencies in different geographic, racial or ethnic groups and the time and resources available for a particular patient. The NMDP will assist transplant centers with requests to worldwide registries and cord blood banks not included in its own file.
The optimal number of potential donors to select from the search report for additional HLA typing should be individualized for each patient since many factors influence the likelihood of finding a compatible donor. Factors to be considered include the patient's alleles and haplotypes (e.g., rare vs. common), as well as clinical urgency. Multiple donors should always be selected since donors may be unavailable, mistyped, or not matched once high-resolution testing is complete. For searches listing numerous potential donors with a high probability of matching, per HapLogic ® or other advanced search algorithms, high-resolution typing of a small number (e.g., 3-5) is usually sufficient. However, in the case of patients with rare alleles and haplotypes, where the likelihood of matching is low, ten or more donors may be required to find the best match. Whenever deemed useful, the NMDP can provide specifically filtered match lists for searches with many donor candidates or with relaxed matching criteria for difficult cases. In the latter situation, help should be immediately sought from a histocompatibility expert (available through the NMDP) to design an effective search strategy that includes evaluation of worldwide donor registries.
How long do I search for adult donors? For patients with common HLA phenotypes, a suitably matched adult donor can usually be identified on the first match run. For patients with uncommon phenotypes, a well-matched donor may not be readily apparent on the initial match run. For these patients, it is recommended that one request help from a local HLA expert or NMDP consultant to assist in identifying the best potential match.
If one is not able to identify an available, acceptably matched volunteer donor in a worldwide search, it is very unlikely that newly recruited donors will match the patient in a useful time frame. The NMDP donor file contains nearly 9.5 million donors (~87% typed for HLA-A, -B, and -DR) and the NMDP search also provides a match report of an additional ~8.5 million donors listed in BMDW, so patients who are not able to find a suitably matched donor in this pool have uncommon HLA phenotypes. The NMDP adds an average of 30,000 new donors to the file monthly. The likelihood that a patient's type will be represented in those new recruits is low. Therefore, it is recommended that one re-evaluate alternative treatment options for those patients and decide whether to reduce the matching requirements or select another graft source (e.g., unrelated cord blood transplantation, partially matched related donor transplantation is not identified after initial screening, -DQB1 and -DRB3/4/5 should be typed to allow selection of the optimal mismatched donor. Testing of loci other than HLA-A, -B, -C, -DRB1 will also support donor selection in the context of an HLA-sensitized patient to avoid the potential risk of graft failure. 29, 30 An HLA expert might recommend a strategy that initially targets selected loci for higher resolution typing to rapidly screen several donors and reduce the typing costs;
however, this approach should be balanced against the patient's medical condition so as not to unduly delay an urgent transplantation.
Cord blood units should be typed by DNA-based methods for HLA-A, -B at a minimum of antigen-level resolution and for DRB1 at high-resolution. Inclusion of HLA-C is strongly recommended. High-resolution typing for all loci helps to ensure that potential allele-level mismatches are well characterized and will allow better evaluation of the impact of HLAmatching in the future.
How "high" does high-resolution typing have to be? High-resolution DNA typing may not always be able to completely distinguish among similar HLA alleles (allele-level resolution).
Current high-resolution techniques focus only on alleles that code for proteins that are found on the cell surface (and so are immunologically "active") and on genes encoding the antigen recognition site (ARS) of HLA molecules. 31 The ARS is the "active" portion of the HLA molecule that binds peptide antigens and interacts with T cell receptors. Available data indicate that alleles that are identical in the ARS domain do not have immunological differences.
Consequently, HLA reports may designate a donor or recipient as having one of several possible alleles, all with the same ARS, for a given locus and it is standard practice to accept identity of these donor and recipient assignments as a match. It is hoped that in the future it may be possible to identify "permissible" mismatches at loci other than DP; however, currently there are currently insufficient data to support this as a standard of practice. Although several schematics for selecting permissive mismatches have been proposed, or A*02:07. However, the challenges of evaluating specific permissive mismatches such as described for the A2 alleles are formidable. A paper assessing the likelihood of retrospectively analyzing permissive mismatches at the HLA-A locus in U.S. recipients estimated that to achieve 80% power to detect an effect of the A2 and several other common mismatches on survival would require a retrospective study of 11,000 to over 1 million donor-recipient pairs. In summary, while selection of a donor matched for HLA-A, -B, -C and -DRB1 at highresolution is preferred, the inability to identify a matched donor is not a contraindication for transplantation. Several strategies exist for selection of a mismatched donor or cord blood unit that will optimize the likelihood of a successful outcome. In many instances, survival rates with a well-selected HLA-mismatched graft are equivalent or nearly equivalent to survival rates after fully matched transplantation. Figure 2 summarizes HLA-related and cell dose factors to consider during the selection of an optimal donor.
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SELECTION OF HLA MISMATCHED DONORS OR CORD BLOOD UNITS
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DONOR SELECTION BASED ON NON-HLA FACTORS
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What non-HLA donor characteristics should I consider? Other non-HLA factors are often considered when selecting donors including CMV negative serology (for CMV negative patients), male gender, younger age, ABO compatibility, prior pregnancies, and larger body weight. To date few reports have focused on donor characteristics as the primary objective. In a large study that specifically addressed donor characteristics by the NMDP, the only donor characteristic other than HLA match to be associated with survival was the age of the donor; mortality risks were higher with increasing donor age. 48 Among cord blood units, the primary non-HLA factor to be considered is cell dose.
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Does the race/ethnicity of the donor need to be the same as the race/ethnicity of the recipient? Some HLA alleles and haplotypes are distributed at different frequencies among different racial/ethnic groups. When searching for a donor, for some alleles, a high-resolution match is more likely to be found amongst persons of the same ancestry as the patient.
HapLogic ® takes the race/ethnicity into account when predicting the likelihood of a highresolution match. Once high-resolution HLA matches are identified, the ancestry of the matched donor does not appear to affect the outcome of the transplant. 8,9,48 It should be recognized that the number of racially/ethnically mismatched donor/recipient pairs in these studies was small and further studies are needed to confirm these data. HLA antibodies HLA-C NIMA Figure 2 
